NO20045528L - MHC1R-antagonister - Google Patents
MHC1R-antagonisterInfo
- Publication number
- NO20045528L NO20045528L NO20045528A NO20045528A NO20045528L NO 20045528 L NO20045528 L NO 20045528L NO 20045528 A NO20045528 A NO 20045528A NO 20045528 A NO20045528 A NO 20045528A NO 20045528 L NO20045528 L NO 20045528L
- Authority
- NO
- Norway
- Prior art keywords
- group
- optionally substituted
- disorders
- alkyl group
- fluorine atoms
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- -1 9,10-methanoanthracene-9 (10H) -yl Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000005936 piperidyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- VUCWMAJEUOWLEY-UHFFFAOYSA-N 1-$l^{1}-azanylpiperidine Chemical compound [N]N1CCCCC1 VUCWMAJEUOWLEY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202134A SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Therapeutic agents |
| PCT/GB2003/002884 WO2004004726A1 (en) | 2002-07-08 | 2003-07-04 | Mchir antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045528L true NO20045528L (no) | 2005-04-04 |
Family
ID=20288471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045528A NO20045528L (no) | 2002-07-08 | 2004-12-17 | MHC1R-antagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060247439A1 (is) |
| EP (1) | EP1528924A1 (is) |
| JP (1) | JP2006501186A (is) |
| CN (1) | CN1665502A (is) |
| AR (1) | AR040476A1 (is) |
| AU (1) | AU2003281194A1 (is) |
| BR (1) | BR0312312A (is) |
| CA (1) | CA2491835A1 (is) |
| CO (1) | CO5680403A2 (is) |
| IL (1) | IL165841A0 (is) |
| IS (1) | IS7653A (is) |
| MX (1) | MXPA05000336A (is) |
| NO (1) | NO20045528L (is) |
| PL (1) | PL374674A1 (is) |
| RU (1) | RU2004138079A (is) |
| SE (1) | SE0202134D0 (is) |
| TW (1) | TW200412957A (is) |
| WO (1) | WO2004004726A1 (is) |
| ZA (1) | ZA200500030B (is) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050197350A1 (en) * | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| CN101475528A (zh) * | 2003-03-31 | 2009-07-08 | 大正制药株式会社 | 新的喹啉、四氢喹唑啉和嘧啶衍生物以及与其应用有关的治疗方法 |
| GB0400193D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
| EP1706384A1 (en) * | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Therapeutic agents i |
| US20090036448A1 (en) * | 2004-03-30 | 2009-02-05 | Taisho Pharmecutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2006015279A1 (en) * | 2004-07-28 | 2006-02-09 | Neurogen Corporation | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders |
| WO2006035967A1 (en) * | 2004-09-30 | 2006-04-06 | Taisho Pharmaceutical Co., Ltd. | Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor |
| US7902356B2 (en) * | 2004-12-17 | 2011-03-08 | Eli Lilly And Company | Thiazolopyridinone derivates as MCH receptor antagonists |
| WO2007087231A2 (en) * | 2006-01-25 | 2007-08-02 | Merck & Co., Inc. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
| WO2008037626A1 (en) * | 2006-09-28 | 2008-04-03 | F. Hoffmann-La Roche Ag | Quinoline derivatives with 5-ht-binding properties |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| PT3252057T (pt) | 2009-12-04 | 2024-06-04 | Sunovion Pharmaceuticals Inc | Compostos multicíclicos e métodos de utilização dos mesmos |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| MX2012015102A (es) | 2010-07-06 | 2013-05-01 | Astrazeneca Ab | Agentes terapeuticos 976. |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| MX2019000982A (es) | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
| EA201990400A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения и композиции и их применение |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| CA3047404A1 (en) * | 2016-12-23 | 2018-06-28 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| CN116808023A (zh) | 2017-02-16 | 2023-09-29 | 桑诺维恩药品公司 | 治疗精神分裂症的方法 |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| MX2020008537A (es) | 2018-02-16 | 2021-01-08 | Sunovion Pharmaceuticals Inc | Sales, formas cristalinas y metodos de produccion de las mismas. |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| CA3180115A1 (en) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
| AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| US20240217951A1 (en) | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US20240228469A1 (en) | 2022-09-23 | 2024-07-11 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US20240239767A1 (en) | 2022-12-16 | 2024-07-18 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN117486758B (zh) * | 2023-10-30 | 2025-12-26 | 南京正济医药研究有限公司 | 一种(1s,3s)-3-氨基环戊基氨基甲酸叔丁酯的制备方法 |
| TW202602866A (zh) | 2024-03-20 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
| TW202539678A (zh) | 2024-03-20 | 2025-10-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
| TW202602886A (zh) | 2024-03-20 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3020283A (en) * | 1958-10-20 | 1962-02-06 | Abbott Lab | Bis-lepidines |
| JPH05507702A (ja) * | 1990-05-30 | 1993-11-04 | アメリカン・ホーム・プロダクツ・コーポレイション | 置換アリールスルホンアミド類およびベンズアミド類 |
| ZA974147B (en) * | 1996-05-14 | 1997-11-14 | Novo Nordisk As | Somatostatin agonists and antagonists. |
| AU4988997A (en) * | 1996-10-23 | 1998-05-15 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
| CA2330564A1 (en) * | 1998-04-29 | 1999-11-04 | John Stephen Elder | Quinolones used as mrs inhibitors and bactericides |
| US6417185B1 (en) * | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| ATE479429T1 (de) * | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
| JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| EP1359915A4 (en) * | 2001-01-26 | 2004-07-21 | Smithkline Beecham | UROTENSIN-II RECEPTOR ANTAGONISTS |
-
2002
- 2002-07-08 SE SE0202134A patent/SE0202134D0/xx unknown
-
2003
- 2003-07-03 TW TW092118207A patent/TW200412957A/zh unknown
- 2003-07-04 CN CN038160749A patent/CN1665502A/zh active Pending
- 2003-07-04 EP EP03740771A patent/EP1528924A1/en not_active Withdrawn
- 2003-07-04 JP JP2004518963A patent/JP2006501186A/ja active Pending
- 2003-07-04 PL PL03374674A patent/PL374674A1/xx not_active Application Discontinuation
- 2003-07-04 AU AU2003281194A patent/AU2003281194A1/en not_active Abandoned
- 2003-07-04 MX MXPA05000336A patent/MXPA05000336A/es not_active Application Discontinuation
- 2003-07-04 RU RU2004138079/04A patent/RU2004138079A/ru not_active Application Discontinuation
- 2003-07-04 BR BR0312312-0A patent/BR0312312A/pt not_active IP Right Cessation
- 2003-07-04 CA CA002491835A patent/CA2491835A1/en not_active Abandoned
- 2003-07-04 US US10/520,372 patent/US20060247439A1/en not_active Abandoned
- 2003-07-04 WO PCT/GB2003/002884 patent/WO2004004726A1/en not_active Ceased
- 2003-07-08 AR AR20030102464A patent/AR040476A1/es unknown
-
2004
- 2004-12-16 IL IL16584104A patent/IL165841A0/xx unknown
- 2004-12-17 NO NO20045528A patent/NO20045528L/no unknown
-
2005
- 2005-01-03 ZA ZA200500030A patent/ZA200500030B/en unknown
- 2005-01-19 IS IS7653A patent/IS7653A/is unknown
- 2005-01-28 CO CO05007427A patent/CO5680403A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IS7653A (is) | 2005-01-19 |
| AU2003281194A1 (en) | 2004-01-23 |
| TW200412957A (en) | 2004-08-01 |
| SE0202134D0 (sv) | 2002-07-08 |
| CA2491835A1 (en) | 2004-01-15 |
| PL374674A1 (en) | 2005-10-31 |
| AR040476A1 (es) | 2005-04-06 |
| RU2004138079A (ru) | 2005-08-10 |
| BR0312312A (pt) | 2005-04-12 |
| WO2004004726A1 (en) | 2004-01-15 |
| IL165841A0 (en) | 2006-01-15 |
| ZA200500030B (en) | 2005-11-11 |
| CO5680403A2 (es) | 2006-09-29 |
| US20060247439A1 (en) | 2006-11-02 |
| EP1528924A1 (en) | 2005-05-11 |
| JP2006501186A (ja) | 2006-01-12 |
| MXPA05000336A (es) | 2005-03-31 |
| CN1665502A (zh) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0202134D0 (sv) | Therapeutic agents | |
| WO2009134617A1 (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
| NO20084302L (no) | 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer | |
| AU2001272476A1 (en) | Piperidines for use as orexin receptor antagonists | |
| ATE381542T1 (de) | Nr1h4-kern-rezeptor-bindende verbindungen | |
| MXPA03006918A (es) | Compuestos heterociclicos fusionados. | |
| WO2006046031A8 (en) | Pharmaceutical compounds | |
| NO20061419L (no) | Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser | |
| NO331068B1 (no) | Benzazepinderivater for behandling av nevrologiske forstyrrelser. | |
| EP1479684A4 (en) | THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME | |
| DE69835877D1 (de) | Trizyklische verbindungen | |
| WO2008107677A3 (en) | Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders | |
| ATE180780T1 (de) | 2-(piperidin-4-yl, pyridin-4-yl und tetrahydropyridin-4-yl)-benzofuran-7-carbamat derivate, ihre herstellung und verwendung als acetylcholinesterase inhibitoren | |
| MY145746A (en) | Heterocyclic substituted pyridine derivatives and antifungal agent containing same | |
| WO2002028853A1 (en) | Benzylamine compound, process for producing the same, and intermediate therefor | |
| NO20080025L (no) | Pyrazolderivater som CB1 modulatorer | |
| MXPA04002569A (es) | H6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas espirociclicas que controlan citocinas inflamatorias. | |
| MX2011007272A (es) | Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1. | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| JO2307B1 (en) | Papermidine derivatives | |
| MXPA04000978A (es) | Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas. | |
| WO1999021848A3 (en) | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands | |
| MY136065A (en) | Prodrugs to nmda receptor ligands | |
| SE0400440D0 (sv) | Novel Cinnamic Amides | |
| GB0428137D0 (en) | Novel herbicides |